Granisetron Torrent Pharma (Uk)

Granisetron Torrent Pharma (Uk) is a prescription intravenous formulation containing the active ingredient granisetron. It is classified as a 5‑HT3 receptor antagonist and is used as an antiemetic. The product is marketed in the European Union and is supplied only with a prescription. It is administered by healthcare professionals under controlled conditions.

Granisetron Torrent Pharma (Uk) is indicated for the prevention of nausea and vomiting associated with specific medical procedures. It is commonly employed in oncology and surgical settings to improve patient comfort.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) - Prevention of postoperative nausea and vomiting (PONV) - Adjunct therapy for radiation‑induced nausea - Use in patients at high risk for emesis due to emetogenic agents - Supportive care in hospice settings where nausea control is needed

Granisetron may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require prompt medical attention.

Common: - Headache - Constipation - Dizziness or light‑headedness - Fatigue or weakness - Diarrhoea - Abdominal discomfort

Serious: - Allergic reactions such as rash, itching, or swelling - QT‑interval prolongation leading to cardiac arrhythmias - Severe hypotension or syncope - Anaphylaxis - Serotonin syndrome when combined with serotonergic agents

Before initiating Granisetron Torrent Pharma (Uk), clinicians should evaluate patient‑specific factors that may influence safety and efficacy. The following precautions are recommended:

- Assess cardiac history, especially QT‑interval abnormalities - Review electrolyte status (potassium, magnesium, calcium) and correct imbalances - Use caution in patients with hepatic or renal impairment; dose adjustment may be required - Consider potential risks in pregnant or breastfeeding women; data are limited - Monitor for signs of hypersensitivity during and after infusion - Evaluate concomitant use of other anti‑emetic agents to avoid overlapping toxicity

Granisetron can interact with several drug classes, affecting its safety profile or therapeutic effect. Awareness of these interactions helps optimize patient care.

Avoid: - Other QT‑prolonging medications (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics) - Concurrent use of other 5‑HT3 antagonists - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may increase granisetron levels

Use with caution: - CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce efficacy - Opioid analgesics that can also cause nausea or constipation - General anaesthetics and muscle relaxants used during surgery - Other serotonergic drugs that could predispose to serotonin syndrome